- $87.54m
- -$125.77m
Annual cashflow statement for Allovir, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -23.8 | -69.8 | -172 | -169 | -190 |
| Depreciation | |||||
| Non-Cash Items | 2.27 | 9.93 | 46.1 | 42.1 | 63.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.4 | -1.03 | 19.4 | -16.1 | 2.02 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -20.2 | -60.8 | -106 | -142 | -124 |
| Capital Expenditures | -0.339 | -0.235 | -0.026 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -64.3 | -169 | 186 | -80.5 | 38 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -64.6 | -169 | 186 | -80.5 | 38 |
| Financing Cash Flow Items | — | -3.47 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 121 | 292 | 0.232 | 127 | 70.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 36.1 | 61.6 | 79.9 | -95.6 | -16 |